Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody-drug conjugate with proven efficacy in metastatic breast cancer, but interstitial lung disease (ILD) and drug-induced pneumonitis are potentially life-threatening toxicities. This evidence concerns the gene ERBB2 and pneumonitis.